Wednesday November 19, 2014
The Health Service Executive has said its drugs committee will meet to reconsider a decision not to fund a life-changing drug for MS sufferers.
Wednesday April 23, 2014
Biogen Idec today reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations.
Thursday April 25, 2013
Biogen Idec today reported higher-than-expected first quarter profit, helped by low taxes and sales growth of its injectable MS treatments.
Wednesday February 06, 2013
Elan has announced a restructuring of its MS drug Tysabri collaboration with Biogen Idec, which will see Biogen getting full ownership and control of multiple sclerosis drug Tysabri.
Monday January 28, 2013
Biogen Idec's fourth-quarter net profit fell slightly due to a tax accounting error.
Wednesday January 16, 2013
Elan and Biogen Idec have filed for approval to sell their drug Tysabri as a first-line treatment for multiple sclerosis.
Thursday September 15, 2011
Elan has named two new non-executive directors to its board.
Thursday April 21, 2011
Biogen Idec released promising data from a clinical trial of its experimental multiple sclerosis drug BG-12 today.
Monday March 08, 2010
Biogen Idec and Roche Holding are suspending their ocrelizumab drug after it caused deaths.
Tuesday October 20, 2009
US biotechnology company Biogen Idec has reported better than expected third-quarter results.